Jiangxi Institute of Biological Products Inc. Class H

Jiangxi Institute of Biological Products Inc. Class H's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Jiangxi Institute of Biological Products Inc. Class H has 308.38M shares outstanding.

As of December 31, 2025, Jiangxi Institute of Biological Products Inc. Class H maintains a current ratio of 4.20, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.18, indicating conservative leverage, while an interest coverage ratio of 3,044.50 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Jiangxi Institute of Biological Products Inc. Class H posted a return on equity (ROE) of 21.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 17.11 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 18.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.01, useful for judging operating efficiency across full business cycles. The company generates approximately 801,172.45 in revenue per employee across its workforce of 327.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.90 indicates how many times Jiangxi Institute of Biological Products Inc. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Jiangxi Institute of Biological Products Inc. Class H recorded 16.10M in income tax expense. That works out to an effective tax rate of 13.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 121.60M, leaving 105.50M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026.

Over the twelve months ended December 31, 2025, Jiangxi Institute of Biological Products Inc. Class H generated 261.98M in revenue and converted that into 105.50M in net income, yielding earnings per share of 0.34. EBITDA reached 115.20M, while operating income came in at 119.44M.

As of December 31, 2025, Jiangxi Institute of Biological Products Inc. Class H holds 82.16M in cash and equivalents against 991,585.68 in total debt, resulting in a net debt position of -82.16M. Total book value stands at 554.24M, with working capital of 218.18M providing operational flexibility.

Jiangxi Institute of Biological Products Inc. Class H produced 63.24M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -34.53M in capital expenditures, free cash flow totaled 28.71M - equivalent to 0.09 per share.

Over the twelve months ended December 31, 2025, Jiangxi Institute of Biological Products Inc. Class H posted a gross margin of 76.75, reflecting its pricing power and cost economics. The operating margin of 45.59 and net profit margin of 40.27 provide insight into operational efficiency.